AML的负担,1990-2019:根据全球疾病负担研究的估计
Chinmay T Jani1,2,3,4, Alaaeldin Ahmed2,3,4, Harpreet Singh4,5
1Sylvester Comprehensive Cancer Center at University of Miami, Miami, FL.
JCO global oncology
|November 22, 2023
概括
全球急性髓性白血病 (AML) 发病率上升,但死亡率正在下降,这表明生存率有所改善. 然而,尽管最近取得了进展,但对一些群体来说,生存趋势可能正在停滞.
科学领域:
- 血液学 血液学 血液学
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 急性髓性白血病 (AML) 是成年人中最常见的急性白血病,不成比例地影响老年人群.
- 治疗的进步改善了年轻患者的治疗结果,但老年人的进展一直较慢,直到最近.
研究的目的:
- 检查1990年至2019年间全球和欧盟 (欧盟) 15+ AML 发病率,死亡率和存活率趋势.
- 确定按性别和年龄组分层的趋势,以了解疾病负担和干预措施的影响.
主要方法:
- 利用全球疾病负担研究的数据,提取年龄标准化发病率 (ASIR) 和年龄标准化死亡率 (ASMR).
- 计算的死亡率与发病率 (MIR) 和Joinpoint回归用于趋势分析,按性别和年龄分层.
主要成果:
- 从1990年到2019年,全球白血病发病率有所增加,大多数欧盟15+国家显示ASIR正在上升.
- 虽然ASMR在全球和欧盟15+国家增加,但近年来死亡率有显著下降.
- 死亡率与发病率 (MIR) 在全球两性都有所改善,这表明生存率更好,55岁及以上的个体承担的负担最高.
结论:
- 该研究表明,AML发病率和死亡率的总体增加,但MIR下降,这表明研究期间的生存率有所改善.
- 结合点分析显示,尽管最近的治疗进展,但在过去十年中,女性的生存趋势和过去四年的男性生存趋势保持稳定.
- 这些发现凸显了持续研究和改进治疗策略的必要性,特别是在老年AML患者中.
更多相关视频
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
3.9K
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.4K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:21Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356